Epigenomics AGFRA:ECX +9.20%13 Median PS Value is €0.00 as of Jul. 01, 2026. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 1149424.14% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-07-01), Epigenomics AG's share price is €0.95. Epigenomics AG's Median PS Value is €0.00. Therefore, Epigenomics AG's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Epigenomics AG's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Epigenomics AG was 2.61. The lowest was 0.04. And the median was 0.81.
FRA:ECX's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.88 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Epigenomics AG (FRA:ECX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Epigenomics AG's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.95
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG Median PS Value Related Terms
Epigenomics AG Median PS Value Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ECX vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epigenomics AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a Median PS Value of €0.00 as of Jul. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Epigenomics AG and its competitors. Over the past decade, Epigenomics AG's Median PS Value has ranged from 0.04 to 2.61. According to the industry distribution chart, Epigenomics AG ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry.
Is Epigenomics AG's Median PS Value too high?
Epigenomics AG's current Median PS Value is €0.00. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 2.61. Based on the distribution chart, Epigenomics AG ranks #999999 out of 87 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #999999 out of 87 companies for Median PS Value. This places Epigenomics AG in the lower half of its industry. The industry median Median PS Value is 0.88. Historically, Epigenomics AG's own Median PS Value has ranged from 0.04 to 2.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.88, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.95 — trading 955.6% above its estimated fair value. The current Median PS Value is €0.00. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Median PS Value is €0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.95 is trading 955.6% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
Median PS Value: €0.00
GF Value™: €0.09 vs. price of €0.95 (955.6% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score
Get the complete analysis for FRA:ECX
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
